Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil

Ying Hong Wang, David R. Jones, Stephen D. Hall

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The genetic basis for polymorphic expression of CYP3A5 has been recently identified, but the significance of CYP3A5 expression is unclear. The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. Testosterone 6β-hydroxylation or midazolam 1'-hydroxylation was used to quantify CYP3A activity. The possibility that verapamil and its metabolites form metabolic-intermediate complex (MIC) with CYP3A was assessed using dual beam spectrophotometry. Verapamil and N-desalkylverapamil (D617) were found to have little inhibitory effect on cDNA-expressed CYP3A5 activity and did not form a MIC with cDNA-expressed CYP3A5 as indicated by the appearance of the characteristic peak at 455 nm. At 50 μM, norverapamil showed time-dependent inhibition of CYP3A5 (30%), but to a much lesser extent compared with that of CYP3A4 (80%). The estimated values of the inactivation parameters kinact and K i of norverapamil were 4.53 μM and 0.07 min-1 for cDNA-expressed CYP3A5, and 10.3 μM and 0.30 min-1 for cDNA-expressed CYP3A4. Human liver microsomes that expressed CYP3A5 were less inhibited by both verapamil and norverapamil. The inactivation efficiency of verapamil and norverapamil was 30 times and 45 times lower, respectively, for CYP3A5-expressing microsomes compared with CYP3A5-non-expressing microsomes. These findings indicate that the presence of variable CYP3A5/CYP3A4 expression in the liver may contribute to the interindividual variability associated with verapamil-mediated drug interactions.

Original languageEnglish
Pages (from-to)664-671
Number of pages8
JournalDrug Metabolism and Disposition
Volume33
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Cytochrome P-450 CYP3A
Verapamil
Complementary DNA
Liver
Hydroxylation
Liver Microsomes
Metabolites
Microsomes
Drug interactions

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. / Wang, Ying Hong; Jones, David R.; Hall, Stephen D.

In: Drug Metabolism and Disposition, Vol. 33, No. 5, 05.2005, p. 664-671.

Research output: Contribution to journalArticle

Wang, Ying Hong ; Jones, David R. ; Hall, Stephen D. / Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. In: Drug Metabolism and Disposition. 2005 ; Vol. 33, No. 5. pp. 664-671.
@article{8c0bc2a4ecd746768d991b9562f43a39,
title = "Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil",
abstract = "The genetic basis for polymorphic expression of CYP3A5 has been recently identified, but the significance of CYP3A5 expression is unclear. The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. Testosterone 6β-hydroxylation or midazolam 1'-hydroxylation was used to quantify CYP3A activity. The possibility that verapamil and its metabolites form metabolic-intermediate complex (MIC) with CYP3A was assessed using dual beam spectrophotometry. Verapamil and N-desalkylverapamil (D617) were found to have little inhibitory effect on cDNA-expressed CYP3A5 activity and did not form a MIC with cDNA-expressed CYP3A5 as indicated by the appearance of the characteristic peak at 455 nm. At 50 μM, norverapamil showed time-dependent inhibition of CYP3A5 (30{\%}), but to a much lesser extent compared with that of CYP3A4 (80{\%}). The estimated values of the inactivation parameters kinact and K i of norverapamil were 4.53 μM and 0.07 min-1 for cDNA-expressed CYP3A5, and 10.3 μM and 0.30 min-1 for cDNA-expressed CYP3A4. Human liver microsomes that expressed CYP3A5 were less inhibited by both verapamil and norverapamil. The inactivation efficiency of verapamil and norverapamil was 30 times and 45 times lower, respectively, for CYP3A5-expressing microsomes compared with CYP3A5-non-expressing microsomes. These findings indicate that the presence of variable CYP3A5/CYP3A4 expression in the liver may contribute to the interindividual variability associated with verapamil-mediated drug interactions.",
author = "Wang, {Ying Hong} and Jones, {David R.} and Hall, {Stephen D.}",
year = "2005",
month = "5",
doi = "10.1124/dmd.104.001834",
language = "English",
volume = "33",
pages = "664--671",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil

AU - Wang, Ying Hong

AU - Jones, David R.

AU - Hall, Stephen D.

PY - 2005/5

Y1 - 2005/5

N2 - The genetic basis for polymorphic expression of CYP3A5 has been recently identified, but the significance of CYP3A5 expression is unclear. The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. Testosterone 6β-hydroxylation or midazolam 1'-hydroxylation was used to quantify CYP3A activity. The possibility that verapamil and its metabolites form metabolic-intermediate complex (MIC) with CYP3A was assessed using dual beam spectrophotometry. Verapamil and N-desalkylverapamil (D617) were found to have little inhibitory effect on cDNA-expressed CYP3A5 activity and did not form a MIC with cDNA-expressed CYP3A5 as indicated by the appearance of the characteristic peak at 455 nm. At 50 μM, norverapamil showed time-dependent inhibition of CYP3A5 (30%), but to a much lesser extent compared with that of CYP3A4 (80%). The estimated values of the inactivation parameters kinact and K i of norverapamil were 4.53 μM and 0.07 min-1 for cDNA-expressed CYP3A5, and 10.3 μM and 0.30 min-1 for cDNA-expressed CYP3A4. Human liver microsomes that expressed CYP3A5 were less inhibited by both verapamil and norverapamil. The inactivation efficiency of verapamil and norverapamil was 30 times and 45 times lower, respectively, for CYP3A5-expressing microsomes compared with CYP3A5-non-expressing microsomes. These findings indicate that the presence of variable CYP3A5/CYP3A4 expression in the liver may contribute to the interindividual variability associated with verapamil-mediated drug interactions.

AB - The genetic basis for polymorphic expression of CYP3A5 has been recently identified, but the significance of CYP3A5 expression is unclear. The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. Testosterone 6β-hydroxylation or midazolam 1'-hydroxylation was used to quantify CYP3A activity. The possibility that verapamil and its metabolites form metabolic-intermediate complex (MIC) with CYP3A was assessed using dual beam spectrophotometry. Verapamil and N-desalkylverapamil (D617) were found to have little inhibitory effect on cDNA-expressed CYP3A5 activity and did not form a MIC with cDNA-expressed CYP3A5 as indicated by the appearance of the characteristic peak at 455 nm. At 50 μM, norverapamil showed time-dependent inhibition of CYP3A5 (30%), but to a much lesser extent compared with that of CYP3A4 (80%). The estimated values of the inactivation parameters kinact and K i of norverapamil were 4.53 μM and 0.07 min-1 for cDNA-expressed CYP3A5, and 10.3 μM and 0.30 min-1 for cDNA-expressed CYP3A4. Human liver microsomes that expressed CYP3A5 were less inhibited by both verapamil and norverapamil. The inactivation efficiency of verapamil and norverapamil was 30 times and 45 times lower, respectively, for CYP3A5-expressing microsomes compared with CYP3A5-non-expressing microsomes. These findings indicate that the presence of variable CYP3A5/CYP3A4 expression in the liver may contribute to the interindividual variability associated with verapamil-mediated drug interactions.

UR - http://www.scopus.com/inward/record.url?scp=17844387084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844387084&partnerID=8YFLogxK

U2 - 10.1124/dmd.104.001834

DO - 10.1124/dmd.104.001834

M3 - Article

VL - 33

SP - 664

EP - 671

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 5

ER -